Table 2 The significant prognostic factors after log-rank test
Clinical subjects | Median survival (95%CI), mons | HR (95%CI) | P-value |
|---|---|---|---|
Age, (years) | Â | Â | 0.20 |
 18–45 | 11.90 (10.08–13.72) | 1 (Reference) | 1.00 |
 46–65 | 12.97 (11.65–14.28) | 0.85 (0.45–1.60) | 0.61 |
  > 65 | 8.13 (6.70–9.57) | 1.12 (0.58–2.17) | 0.81 |
Gender | |||
 Female | 13.43 (11.95–14.92) | 1 (Reference) | 1.00 |
 Male | 9.63(8.44–10.83) | 1.04 (0.75–1.47) | 0.80 |
History of smoking | |||
 None | 14.13 (12.42–15.85) | 1 (Reference) | 1.00 |
 Yes | 9.23 (7.92–10.55) | 1.42(1.02–1.96) | 0.04 |
 Unknown | NA | NA | NA |
KPS | Â | Â | 0.67 |
 10–40 | 14.47 (0.00–40.30) | 1 (Reference) | 1.00 |
 50–70 | 8.30 (4.88–11.72) | 2.28 (0.77–6.79) | 0.14 |
 80–100 | 12.43 (11.12–13.74) | 1.94 (0.67–5.63) | 0.22 |
 Unknown | NA | NA | NA |
Lymph node metastasis | |||
 None | 13.37 (11.33–15.40) | 1 (Reference) | 1.00 |
 Yes | 10.77 (9.56–11.98) | 1.10 (0.81–1.45) | 0.51 |
 Unknown | NA | NA | NA |
Pathology | Â | Â | 0.03 |
 Small-cell | 10.10 (7.48–12.73) | 1.22 (0.78–1.91) | 0.38 |
 Adenocarcinoma | 15.67 (13.22–18.12) | 1 (Reference) | 1.00 |
 Squamous cell | 9.73 (7.62–11.85) | 1.42 (0.98–2.05) | 0.06 |
 Large cell | 8.67 (2.99–14.34) | 1.85 (0.80–4.30) | 0.15 |
 Mixed | 7.10 (4.15–10.05) | 2.09 (1.11–3.94) | 0.02 |
 Unknown | NA | NA | NA |
LDH | |||
  < 215.00 U/L | 13.43 (11.90–14.96) | 1 (Reference) | 1.00 |
  ≥ 215.00 U/L | 8.67 (7.37–9.97) | 1.12 (0.82–1.51) | 0.48 |
 Unknown | NA | NA | NA |
Cyfra21–1 | |||
  < 4.93 ng/ml | 15.33 (13.36–17.31) | 1 (Reference) | 1.00 |
  ≥ 4.93 ng/ml | 8.30 (7.17–9.43) | 1.26 (0.93–1.71) | 0.13 |
 Unknown | NA | NA | NA |
NSE | |||
  < 16.67 ng/ml | 15.00 (12.74–17.27) | 1 (Reference) | 1.00 |
  ≥ 16.67 ng/ml | 9.23 (7.86–10.61) | 1.42 (1.06–1.92) | 0.02 |
 Unknown | NA | NA | NA |